Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.

ABSTRACT: Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD¹; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.

SUBMITTER: Rudra S 

PROVIDER: S-EPMC8792097 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature